Johnson & Johnson (NYSE:JNJ) announced that it temporarily paused further dosing in its COVID-19 vaccine candidate clinical trials.
The pause in the trials conducted by J&J’s Janssen Pharmaceuticals subsidiary follows an unexplained illness arising in a study participant, according to a news release. Under the company’s guidelines, the illness is being reviewed and evaluated by internal and independent investigators.
Get the full story at our sister site, Drug Discovery & Development.